Financials NeuBase Therapeutics, Inc. Nasdaq
Equities
NBSE
US64132K2015
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.378 USD | -3.20% |
|
-.--% | -48.93% |
Jun. 27 | NeuBase Therapeutics, Inc. Announces Board Resignations | CI |
May. 29 | NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding | CI |
Valuation
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Capitalization 1 | 81.25 | 146.8 | 102.1 | 12.06 | 1.278 |
Enterprise Value (EV) 1 | 81.25 | 146.8 | 102.1 | 12.06 | 1.278 |
P/E ratio | - | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | -24,617,554 x | - | - | - | - |
FCF Yield | -0% | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 854 | 1,156 | 1,636 | 1,613 | 3,752 |
Reference price 2 | 95.20 | 127.0 | 62.40 | 7.480 | 0.3406 |
Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -26.34 | -17.07 | -26.57 | -33.32 | -14.01 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -26.96 | -17.38 | -25.41 | -33.78 | -12.32 |
Net income 1 | -26.96 | -17.38 | -25.41 | -33.78 | -12.32 |
Net margin | - | - | - | - | - |
EPS | - | - | - | - | - |
Free Cash Flow | -3.301 | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
Balance Sheet Analysis
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | -3.3 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | 0.46 | - | - | - | 1.2 |
Capex / Sales | - | - | - | - | - |
Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- O7P Stock
- NBSE Stock
- Financials NeuBase Therapeutics, Inc.